Early Detection of Relapse in Ovarian Cancer Using Capillary Home-sampling and a Protein Biomarker Test

Launched by UPPSALA UNIVERSITY HOSPITAL · May 31, 2024

Keywords

ClinConnect Summary

This clinical trial is studying a new way to detect if ovarian cancer is coming back in women who have finished their initial treatment and currently show no signs of the disease. The researchers want to see if a simple home blood test, which involves taking a small sample from a finger, can accurately identify early signs of cancer relapse using a specific protein marker. This study is particularly important because detecting cancer early can lead to better treatment outcomes and longer survival.

To participate, women must be at least 18 years old and enrolled in a follow-up program for ovarian, fallopian tube, or peritoneal cancer at specific hospitals in Sweden. They should be within three years of completing their primary treatment and must have no current evidence of cancer. Participants will take the home blood test every two months for a year, and while the test results won't change their treatment, they will help the researchers learn more about how to improve monitoring for cancer relapse in the future. This study could also lead to more personalized follow-up options for women based on their individual needs and preferences.

Gender

FEMALE

Eligibility criteria

• Inclusion Criteria:
• • ≥18 years of age
• • Included in the control program for ovarian/fallopian/primary peritoneal cancer at at Uppsala University Hospital, Uppsala or in Norrlands University Hospital, Umeå,
• • Within 3 years after completed primary treatment for stage III-IV epithelial ovarian cancer, or after treatment for relapse
• • No evidence of disease (normal CA 125 and no tumor detected on radiology or clinical examination).
• Exclusion Criteria:
• • Other cancer diagnosis within 2 years (except squamous skin cancer or basalioma).
• • Non-Swedish speaking.
• • Not able to understand instructions.

Trial Officials